<DOC>
	<DOCNO>NCT01724476</DOCNO>
	<brief_summary>The investigator propose conduct randomize Sequential Parallel Design Double-Blind Phase fix dose , 4-month trial folate plus B12 add-on therapy 200 Ethiopian subject schizophrenia stable residual positive negative symptom .</brief_summary>
	<brief_title>A Trial Folate With B12 Patients With Schizophrenia With Residual Symptoms Ethiopia</brief_title>
	<detailed_description>This 16-week , randomize , double-blind , placebo-controlled study Folate 2mg plus B12 400mcg , adjunctive therapy approximately 240 consecutive outpatient schizophrenia Amanuel Hospital , base Addis Ababa , Ethiopia enrol screened eligibility . The goal randomize complete 200 subject 240 enrol . A Sequential Parallel Design Double-Blind Phase utilized . During first phase double-blind adjunctive treatment , eligible patient ( n=200 ) randomize adjunctive treatment either folate vitamin B12 ( n=60 ) placebo ( n=150 ) , 2:3:3 ratio random assignment treatment sequence drug/drug ( DD ; n=70 ) , placebo/placebo ( PP ; n=70 ) , placebo/drug ( PD ; n=75 ) , continue receive antipsychotic agent entire duration study . Assuming 10 % drop-out rate first phase , 126 patient placebo complete first 56-day phase , 54 patient folate vitamin B12 complete first 56-day phase .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Folic Acid</mesh_term>
	<mesh_term>Vitamin B Complex</mesh_term>
	<criteria>1 . Diagnosis schizophrenia , subtype 2 . Male female 3 . Age 1865 year 4 . Treated antipsychotic least 6 month stable dose least 6 week 5 . PANSS total score least 60 , least 3 ( moderate ) one negative symptom item one positive symptom item . 6 . No acute medical problem ; chronic medical condition ( e.g . hypertension ) consistently treat stable 1 month prior participation 1 . Unable provide inform consent 2 . Serum B12 concentration le 300mcg/L ; Complete Blood Count ( CBC ) result consistent megaloblastic anemia 3 . Serum creatinine concentration great 1.4 4 . Current use folate B12 supplementation 5 . Current use follow medication : phenobarbital , phenytoin , carbamazepine , valproic acid , fosphenytoin , primidone pyrimethamine ; antimalarial drug 6 . Alcohol substance abuse within 3 month ( nicotine allow ) 7 . Subjects history clinically significant neurological , metabolic , hepatic , renal , hematological , pulmonary , cardiovascular , gastrointestinal , and/or urological disorder ( e.g . unstable angina , decompensated congestive heart failure , Central Nervous System ( CNS ) infection history HIV seropositivity ) , would pose risk patient participate study might confound result study . Active medical condition minor well control exclusionary affect risk patient study result . For example , follow exclusionary : ) stable well controlled hypertension ; b ) asthma ( serious attack past year ) 8 . Unstable psychiatric illness 9 . Seizure disorder 10 . Pregnancy nursing</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>